ADC R&D Platform
Delivering potent payloads
In the formulation of Antibody Drug Conjugate (ADC) preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers.
Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of the end of 2023, Medicilon has successfully assisted in the clinical approval of 23 ADC drugs and has 20+ ADC projects under development.